Needham & Company LLC initiated coverage on shares of Athenex (NASDAQ:ATNX) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $30.00 price objective on the stock.
A number of other equities analysts have also issued reports on ATNX. BidaskClub lowered shares of Athenex from a hold rating to a sell rating in a research report on Thursday, January 4th. Deutsche Bank set a $20.00 price target on shares of Athenex and gave the company a buy rating in a report on Wednesday, January 17th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Athenex from $22.20 to $23.00 and gave the company a neutral rating in a report on Wednesday, January 24th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Athenex presently has an average rating of Buy and a consensus price target of $28.17.
Athenex (ATNX) opened at $16.72 on Tuesday. Athenex has a 52-week low of $11.21 and a 52-week high of $20.79.
Several large investors have recently modified their holdings of the company. Millennium Management LLC boosted its stake in shares of Athenex by 170.1% in the 4th quarter. Millennium Management LLC now owns 64,002 shares of the company’s stock valued at $1,018,000 after purchasing an additional 40,302 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Athenex by 176.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 87,427 shares of the company’s stock valued at $1,390,000 after purchasing an additional 55,795 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Athenex by 190.8% in the 4th quarter. Deutsche Bank AG now owns 18,511 shares of the company’s stock valued at $293,000 after purchasing an additional 12,146 shares in the last quarter. Prince Street Capital Management LLC acquired a new stake in shares of Athenex in the 4th quarter valued at $2,798,000. Finally, Geode Capital Management LLC boosted its stake in shares of Athenex by 29.8% in the 4th quarter. Geode Capital Management LLC now owns 116,809 shares of the company’s stock valued at $1,857,000 after purchasing an additional 26,833 shares in the last quarter. Institutional investors own 5.95% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3252810/athenex-atnx-now-covered-by-analysts-at-needham-company-llc.html.
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.